New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:15 EDTLMNX, HOLX, AFFX, SIEGY, LIFE, BDX, ABT, RHHBY, ILMN, A, ENZEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Enzo Biochem (ENZ) announced today that U.S. District Judge Leonard P. Stark has established August 18th as the date for a patent claim construction hearing, also called a Markman hearing, involving Enzo Life Science’s U.S. Patents Nos. 6,992,180, 7,064,197, and 8,097,405. The hearing will be held in Delaware District Court. One or more of these patents is asserted against Abbott Labs (ABT), Affymetrix (AFFX), Agilent (A), Becton Dickinson (BDX), Gen-Probe, Hologic (HOLX), Illumina (ILMN), Life Technologies (LIFE), Luminex (LMNX), Roche (RHHBY), and Siemens (SIEGY), and their related entities. At such a hearing, the Judge will be asked to issue rulings regarding the language and interpretation of Enzo's patents at issue in the case. Markman hearings are considered a key event in a patent lawsuit. The upcoming Markman ruling will define the property rights for the technologies that Enzo has invented. Such rulings often drive and inform many aspects of the litigation.
News For ENZ;ABT;AFFX;A;BDX;HOLX;ILMN;LIFE;LMNX;RHHBY;SIEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 27, 2015
14:14 EDTBDXRetractable Technologies announces amended final judgement, notice of appeal
Retractable Technologies (RVP) announced that on April 23, the United States District Court for the Eastern District of Texas, Marshall Division, entered an amended final judgment in Retractable Technologies' suit against Becton, Dickinson and Company (BDX) for antitrust and other claims. The Amended Final Judgment states: 1. Becton, Dickinson and Company attempted to monopolize the safety syringe market. 2. Becton, Dickinson and Company committed false advertising under the Lanham Act. 3. Retractable Technologies recovers from Becton, Dickinson and Company: $340.52M. 4. Retractable Technologies recovers from Becton, Dickinson and Company its attorneys’ fees in the amount of $11.72M. 5. Retractable Technologies is further awarded post-judgment interest and costs. 6. The court grants injunctive relief consistent with its prior orders. On April 24, Becton, Dickinson and Company filed a notice of appeal announcing its appeal of the amended final judgment and various other post-trial and post judgment orders to the United States Court of Appeals for the Fifth Circuit.
11:54 EDTHOLXHologic management to meet with Jefferies
Meeting to be held in New York on May 1 hosted by Jefferies.
11:19 EDTILMNOptions with decreasing implied volatility
Subscribe for More Information
06:19 EDTRHHBYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
11:02 EDTAAgilent announces strategic collaboration with National University of Singapore
Subscribe for More Information
10:03 EDTILMNIllumina upgraded to Strong Buy from Buy at Tigress Financial
Subscribe for More Information
09:02 EDTSIEGYSiemens says FDA approves breast tomosynthesis option for mammography platform
Subscribe for More Information
April 22, 2015
16:15 EDTAAgilent announces resolution to FDA warning letter for Dako Denmark
Subscribe for More Information
14:11 EDTILMNIllumina falls after results, price target bumps
Subscribe for More Information
13:30 EDTILMNIllumina weakness a buying opportunity, says Cowen
Subscribe for More Information
09:26 EDTABTAbbott sees flat growth in Molecular Diagnostics business in Q2
Sees mid-single digit growth for Global Diagnostics growth in Q2. Sees low single digit growth for Global Vascular in Q2. Expects similar double digit growth in EPD in Q2.
09:21 EDTABTAbbott sees FY15 revenue growth to be in low single digits, consensus $20.71B
Subscribe for More Information
09:20 EDTABTAbbott sees Q2 EPS 49c-51c, consensus 52c
Subscribe for More Information
07:48 EDTABTAbbott reports Q1 Nutrition sales up 6.3% to $1.67B
Subscribe for More Information
07:46 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.14
Subscribe for More Information
07:45 EDTABTAbbott reports Q1 adjusted EPS 47c, consensus 42c
Subscribe for More Information
06:40 EDTILMNIllumina price target raised to $240 from $215 at Citigroup
Subscribe for More Information
06:05 EDTILMNIllumina price target raised to $230 from $220 at Mizuho
Subscribe for More Information
05:27 EDTRHHBYRoche sees FY15 core EPS to grow ahead of sales at constant exchange rates
Expects FY15 sales to grow low- to mid-single digit, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
05:27 EDTRHHBYRoche reports Q1 group sales CHF 11.83B vs. CHF 11.50B
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use